Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, July 01, 2015 (GLOBE NEWSWIRE) --
Imprimis Pharmaceuticals, Inc. (Nasdaq:IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded ophthalmic and urologic drug formulations, will visit the Nasdaq MarketSite in Times Square in celebration of the growing success of its Go Dropless™ campaign. Over 3.6 million cataract procedures are performed annually in the U.S. and more than 4.3 million are expected by 2017. Leading ophthalmologists and their patients are reporting on the many advantages of the company’s Dropless Cataract Surgery™ injectable formulations, which may include reducing or eliminating the need for post-surgical eye drops and providing tremendous cost savings to the U.S. healthcare system.
In honor of the occasion, Mark L. Baum, Founder and CEO, and other members of the Imprimis team will ring the Closing Bell.
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Thursday, July 2, 2015 – 3:45 p.m. to 4:00 p.m. ET
Imprimis Pharmaceuticals, Inc. Media Contact:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/
A webcast of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Imprimis Pharmaceuticals, Inc. (Nasdaq:IMMY):
San Diego-based Imprimis Pharmaceuticals, Inc. is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at accessible prices. Imprimis’ business is focused on its proprietary ophthalmology and urology drug formulations. The company’s pioneering ophthalmology formulation portfolio is disrupting the multi-billion dollar eye drop market, addressing patient compliance issues and providing other medical and economic benefits to patients. Imprimis recently launched its urology business, which includes a patented formulation to address patients suffering from interstitial cystitis and lyophilized compounded formulations for men with erectile dysfunction. For more information about Imprimis, please visit the company’s corporate website at www.ImprimisPharma.com; ophthalmology business websites at www.GoDropless.com and www.LessDrops.com; and urology business websites at www.DefeatIC.com and www.EDfree.com.
All Imprimis formulations may be prescribed pursuant to a physician prescription for an individually identified patient consistent with federal and state laws governing compounded drug formulations.
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of approximately $9.5 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.
In This StoryNDAQ
Nasdaq Press Center
Read the latest press releases, request a press kit, and get in touch with our press team.